Terms: = Breast cancer AND NF2, ACN, 4771, ENSG00000186575, P35240, SCH, Merlin, BANF AND Treatment
32 results:
1. Hyaluronic acid-based injectable formulation developed to mitigate metastasis and radiation-induced skin fibrosis in breast cancer treatment.
Wang YC; Shueng PW; Hu CY; Tung FI; Chen MH; Liu TY
Carbohydr Polym; 2024 Jul; 336():122136. PubMed ID: 38670762
[TBL] [Abstract] [Full Text] [Related]
2. The Use of schisandrin B to Combat Triple-Negative breast cancers by Inhibiting NLRP3-Induced Interleukin-1β Production.
Chang CM; Liang TR; Lam HYP
Biomolecules; 2024 Jan; 14(1):. PubMed ID: 38254674
[TBL] [Abstract] [Full Text] [Related]
3. Targeted Intervention of nf2-YAP Signaling Axis in CD24-Overexpressing Cells Contributes to Encouraging Therapeutic Effects in TNBC.
Hou L; Pu L; Chen Y; Bai Y; Zhou Y; Chen M; Wang S; Lv Y; Ma C; Cheng P; Zhang K; Liang Q; Deng S; Wang D
ACS Nano; 2022 Apr; 16(4):5807-5819. PubMed ID: 35420780
[TBL] [Abstract] [Full Text] [Related]
4. Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With breast cancer or Ovarian cancer, 2012-2019.
Kurian AW; Ward KC; Abrahamse P; Bondarenko I; Hamilton AS; Deapen D; Morrow M; Berek JS; Hofer TP; Katz SJ
J Clin Oncol; 2021 May; 39(15):1631-1640. PubMed ID: 33560870
[TBL] [Abstract] [Full Text] [Related]
5. A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies.
Collier KA; Valencia H; Newton H; Hade EM; Sborov DW; Cavaliere R; Poi M; Phelps MA; Liva SG; Coss CC; Wang J; Khountham S; Monk P; Shapiro CL; Piekarz R; Hofmeister CC; Welling DB; Mortazavi A
Cancer Chemother Pharmacol; 2021 May; 87(5):599-611. PubMed ID: 33492438
[TBL] [Abstract] [Full Text] [Related]
6. Disease course of neurofibromatosis type 2: a 30-year follow-up study of 353 patients seen at a single institution.
Forde C; King AT; Rutherford SA; Hammerbeck-Ward C; Lloyd SK; Freeman SR; Pathmanaban ON; Stapleton E; Thomas OM; Laitt RD; Stivaros S; Kilday JP; Vassallo G; McBain C; Kerrigan S; Smith MJ; McCabe MG; Harkness EF; Evans DG
Neuro Oncol; 2021 Jul; 23(7):1113-1124. PubMed ID: 33336705
[TBL] [Abstract] [Full Text] [Related]
7. Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing.
Lang GT; Jiang YZ; Shi JX; Yang F; Li XG; Pei YC; Zhang CH; Ma D; Xiao Y; Hu PC; Wang H; Yang YS; Guo LW; Lu XX; Xue MZ; Wang P; Cao AY; Ling H; Wang ZH; Yu KD; Di GH; Li DQ; Wang YJ; Yu Y; Shi LM; Hu X; Huang W; Shao ZM
Nat Commun; 2020 Nov; 11(1):5679. PubMed ID: 33173047
[TBL] [Abstract] [Full Text] [Related]
8. cancer genomics of lung cancer including malignant mesothelioma: A brief overview of current status and future prospects.
Jhanwar SC; Xu XL; Elahi AH; Abramson DH
Adv Biol Regul; 2020 Dec; 78():100723. PubMed ID: 32992231
[TBL] [Abstract] [Full Text] [Related]
9. Antitumor potential of dark sweet cherry sweet (Prunus avium) phenolics in suppressing xenograft tumor growth of MDA-MB-453 breast cancer cells.
Noratto G; Layosa MA; Lage NN; Atienza L; Ivanov I; Mertens-Talcott SU; Chew BP
J Nutr Biochem; 2020 Oct; 84():108437. PubMed ID: 32615370
[TBL] [Abstract] [Full Text] [Related]
10. Subclinical hypothyroidism and the risk of cancer incidence and cancer mortality: a systematic review.
Gómez-Izquierdo J; Filion KB; Boivin JF; Azoulay L; Pollak M; Yu OHY
BMC Endocr Disord; 2020 Jun; 20(1):83. PubMed ID: 32517676
[TBL] [Abstract] [Full Text] [Related]
11. Matrix stiffness modulates ILK-mediated YAP activation to control the drug resistance of breast cancer cells.
Qin X; Lv X; Li P; Yang R; Xia Q; Chen Y; Peng Y; Li L; Li S; Li T; Jiang Y; Yang H; Wu C; Zheng C; Zhu J; You F; Wang H; Chen J; Liu Y
Biochim Biophys Acta Mol Basis Dis; 2020 Mar; 1866(3):165625. PubMed ID: 31785406
[TBL] [Abstract] [Full Text] [Related]
12. Regulation of the Hippo Pathway by Phosphatidic Acid-Mediated Lipid-Protein Interaction.
Han H; Qi R; Zhou JJ; Ta AP; Yang B; Nakaoka HJ; Seo G; Guan KL; Luo R; Wang W
Mol Cell; 2018 Oct; 72(2):328-340.e8. PubMed ID: 30293781
[TBL] [Abstract] [Full Text] [Related]
13. schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation.
Zhang ZL; Jiang QC; Wang SR
Breast Cancer; 2018 Mar; 25(2):233-242. PubMed ID: 29181822
[TBL] [Abstract] [Full Text] [Related]
14. Cellular prion protein (PrP
Provenzano L; Ryan Y; Hilton DA; Lyons-Rimmer J; Dave F; Maze EA; Adams CL; Rigby-Jones R; Ammoun S; Hanemann CO
Oncogene; 2017 Nov; 36(44):6132-6142. PubMed ID: 28692055
[TBL] [Abstract] [Full Text] [Related]
15. Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer.
de Oliveira Taveira M; Nabavi S; Wang Y; Tonellato P; Esteva FJ; Cantley LC; Wulf GM
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1255-1262. PubMed ID: 28247034
[TBL] [Abstract] [Full Text] [Related]
16. 15α-methoxypuupehenol Induces Antitumor Effects
Hilliard TS; Miklossy G; Chock C; Yue P; Williams P; Turkson J
Mol Cancer Ther; 2017 Apr; 16(4):601-613. PubMed ID: 28069875
[TBL] [Abstract] [Full Text] [Related]
17. A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (sch 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer.
Mitri Z; Karakas C; Wei C; Briones B; Simmons H; Ibrahim N; Alvarez R; Murray JL; Keyomarsi K; Moulder S
Invest New Drugs; 2015 Aug; 33(4):890-4. PubMed ID: 25947565
[TBL] [Abstract] [Full Text] [Related]
18. Role of merlin/nf2 inactivation in tumor biology.
Petrilli AM; Fernández-Valle C
Oncogene; 2016 Feb; 35(5):537-48. PubMed ID: 25893302
[TBL] [Abstract] [Full Text] [Related]
19. Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer.
Moulder S; Helgason T; Janku F; Wheler J; Moroney J; Booser D; Albarracin C; Morrow PK; Atkins J; Koenig K; Gilcrease M; Kurzrock R
Ann Oncol; 2015 Jul; 26(7):1346-52. PubMed ID: 25878190
[TBL] [Abstract] [Full Text] [Related]
20. The p53/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours.
Ammoun S; Schmid MC; Zhou L; Hilton DA; Barczyk M; Hanemann CO
Mol Oncol; 2015 Jan; 9(1):236-48. PubMed ID: 25217104
[TBL] [Abstract] [Full Text] [Related]
[Next]
